Amryt Pharma (Amryt Pharma) Long-Term Capital Lease Obligation : $3.2 Mil (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Long-Term Capital Lease Obligation?

Amryt Pharma's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2022 was $3.2 Mil.

Amryt Pharma's quarterly Long-Term Capital Lease Obligation increased from Mar. 2022 ($0.0 Mil) to Jun. 2022 ($3.5 Mil) but then declined from Jun. 2022 ($3.5 Mil) to Sep. 2022 ($3.2 Mil).

Amryt Pharma's annual Long-Term Capital Lease Obligation declined from Dec. 2019 ($1.1 Mil) to Dec. 2020 ($0.0 Mil) but then stayed the same from Dec. 2020 ($0.0 Mil) to Dec. 2021 ($0.0 Mil).

Amryt Pharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Amryt Pharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Long-Term Capital Lease Obligation Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.05

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															4.21	-	-	3.54	3.23

Amryt Pharma (NAS:AMYT) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Amryt Pharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).